Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So the greater than 10 is real and we're really excited about the growth that we've been able to see in that part of our business |
| We believe this unique experience positions Societal well to address the emerging psychedelic therapy sector, as well as the growing number of ongoing and planned clinical trials in this area |
| As I have outlined today, the third quarter was a highly productive time during which the company's operational performance was strong |
| As a result of our rebranding and related marketing activities, as well as the consistent efforts of our business development team for the past couple of years, the company's name recognition has increased in the CDMO space, and resulted in the strong lead generation that continues to fuel our product pipeline |
| We're very excited to have such a strong portfolio of projects at this stage |
| These projects span a range of societal capabilities, and we believe speak to the growing strength of our reputation within the industry and track record of success with our existing customers |
| The efforts of the third quarter demonstrated the company's ability to continue to attract new pipeline projects, raise capital and rapidly re-orient the business to best serve existing and new customers despite today's challenging market conditions |
| When we combine these achievements with our expectations for 2024 and 2025, we believe we are firmly on the path to a steadily growing business generating positive cash flow |
| When combined with our improved debt structure, as well as the proceeds from our recent financing, we believe that we are well positioned not only to weather today's difficult environment, but we believe we have created a path to future growth, cash flow, positivity, and ultimately sustainable profitability |
| And we do expect to generate positive cash flow from operations next year and also be free cash flow positive in 2024 |
| So we do expect improvement in gross margins, I think in the high 20% range |
| And so, I think it's good for the business that those get approved, and we see it's actually more like 12 or 13 of those programs |
| right now; we believe that Societal CDMO is well positioned to achieve steady growth in the near-term, and are positioned to reach positive cash flow in 2025 |
| Given our years of experience handling controlled substances, we believe we are uniquely qualified to support the emerging psychedelic therapy sector, as well as the growing number of ongoing and planned clinical trials in this area, and we're very excited to be working in this innovative area of drug development |
| We are grateful for their trust and partnership and we view this as a strong indicator for our ability to build our customer base, project pipeline, and backlog in the future |
| We believe that these improved economics will further strengthen our financial position and facilitate the continued growth of our CDMO business |
| During the third quarter, Societal successfully executed a number of important objectives with the intent not only of strengthening our customer base and backlog, but also establishing a stronger financial platform from which to navigate the challenging financial environment that continues to impact the businesses and related decision-making many of our existing and prospective customers |
| Matt has a track record of success supporting micro cap, small cap and mid cap healthcare companies, and we are thrilled to have expanded access to his experience in guiding companies towards growth and sustainable profitability |
| And finally, we expect to execute new marketing contracts for Verapamil that we believe will increase our profit levels due to favorable economics for this important part of our revenue portfolio |
| When we view the company's 2023 achievements today, in the context of expectations for 2024 and beyond, we are bullish on our prospects for growth in the near future |
| Also during the quarter, the company continued to successfully add multiple new and existing customer projects to our pipeline |
| As a result, our balance sheet has improved significantly in recent quarters and we believe our financial standing will continue to strengthen in 2024 due to a number of factors |
| As we begin planning for those contracts to be revisited, early indications give us confidence that the economics of the new Verapamil contracts will be measurably improved for Societal |
| These Phase 3 to commercial ramping activities are highly profitable for the company |
| While we have scaled back much of our early stage work, we continue to successfully support several early stage programs that are advancing through the clinic, each with increasing manufacturing demands |
| Given this improved debt structure, we were able to further fortify our financial position during the third quarter by closing a public offering of common stock, raising gross proceeds of approximately $8.3 million |
| When you consider these achievements, and our building of a CDMO over the past three to four years, on the back of an enterprise with legacy commercial manufacturing experience measured in decades, and combine that with increasingly optimistic projections for CDMO outsourcing trends in our industry, particularly in the U.S |
| Over the last few months, we've also had a number of notable corporate achievements |
| We have high conviction that the current market valuation of our company is not at all reflective of, nor indicative of the real value of the company we have built and continue to grow every day |
| While we believe these decisions will drive improved cash flow for the company, they will also reduce the company's overall revenue generating capacity in the near-term by approximately 5% to 10% |
| Statement |
|---|
| Given today's market dynamics that continue to create financing risk for drug developers, it's important to emphasize that Societal continues to win important projects being advanced by both, new and existing customers |
| The $1 million decrease in EBITDA is primarily due to higher expenses during the period as discussed previously |
| Certainly there are a lot of cell and gene therapy programs that are cycling through the system, for good and bad, and faced with some challenges there |
| Offsetting these increases were a decrease in Novartis and InfectoPharm shipments due to timing of customer orders, as well as prior year inventory builds for InfectoPharm as a then new customer |
| Maybe first up, regarding the market, obviously, it's been a challenging environment to say the least, but have you seen any changes over the last 90 days? Some companies out there are saying that they are starting to see some green shoots emerging, and some customers starting to talk about programs and projects, and maybe those could start here at Q4 but more likely Q1 of the New Year |
| Hand-in-hand with a reduction of our workforce, we have also made decisions to scale back or discontinue aspects of our operations which will impact the company's manufacturing capacity and accordingly our revenue generating capability |
| The $4.3 million decrease in EBITDA is primarily due to a mix of revenues and related fixed cost absorption, offset by reduced selling, general and administrative costs |
| For the quarter ended September 30, 2023, the company recorded a net loss of $4.6 million or $0.05 per diluted share as compared to a net loss of $3.3 million or $0.06 per diluted share for the comparable period of 2022 |
| I mean that part of the market is certainly getting a lot of attention; it's early days as you pointed out first, but they too are struggling from a financing perspective |
| We have also opted to discontinue certain early stage operations that have been recently under-utilized as a result of the financing market pullback |
| And I think that that that clarification and that lack of uncertainty is what everybody has been looking for |
| For the nine months ended September 30, 2023, Societal reported a net loss of $12.5 million or $0.14 per diluted share compared to a net loss of $10.7 million or $0.19 per diluted share for 2022 |
| As a result of our restructuring and our strategic refocusing of assets; we are today resetting our 2023 revenue guidance to account for the discontinuation of certain programs and services to between $92 million and $94 million, and EBITDA as adjusted guidance to between $11.5 million and $13 million |
| It's important to note that a significant majority of the cuts will impact the portion of the business supporting earlier stage services, which are most acutely affected by the current financing environment |
Please consider a small donation if you think this website provides you with relevant information